Study Condition(s): Mild Alzheimer's, Mild Cognitive Impairment
A Study of Lanabecestat (LY3314814) in Participants With Early Alzheimer's Disease Dementia
Study Alias: AZFD
This study is an extension of study I8D-MC-AZES (NCT02245737), the AMARANTH study. The purpose of this study is to evaluate the effectiveness of the study drug LY3314814 in participants with early Alzheimer's disease dementia at the time of entry into study I8D-MC-AZES.
Key Participation Requirements
All clinical trials have rules about who can participate. This section outlines some of those rules. Please contact a study center to discuss the full set of criteria
- Participants must have been previously enrolled in AMARANTH (NCT02245737) study